Table 2 Baseline characteristics of the patients.
Characteristic | Rivaroxaban (n = 35) | Standard therapy (n = 32) | Total (n = 67) | p - value |
|---|---|---|---|---|
Age (yr), mean ± SD | 57.3 ± 11.1 | 60.1 ± 10.9 | 58.7 ± 11.0 | 0.31 |
Male, n (%) | 15 (42.9) | 13 (40.6) | 28 (41.8) | 0.85 |
Body mass index (kg/m2) | 24.5 ± 3.8 | 24.6 ± 4.2 | 24.6 ± 7.6 | 0.98 |
Comorbidities, n (%) | ||||
- Diabetes mellitus | 5 (14.3) | 0 | 5 (7.5) | 0.05 |
- Hypertension | 9 (25.7) | 13 (40.6) | 22 (32.8) | 0.19 |
- Ischemic heart disease | 1 (2.9) | 1 (3.1) | 2 (3) | 1.00 |
- Chronic kidney disease | 0 | 1 (3.1) | 1 (1.5) | 0.49 |
Use of antiplatelets, n (%) | ||||
- Aspirin | 3 (8.6) | 3 (9.4) | 6 (9.0) | 1.00 |
Risk factors, n (%) | ||||
- Surgery (3 mo) | 6 (17.1) | 4 (12.5) | 10 (14.9) | 0.74 |
- Trauma (3 mo) | 7 (20.0) | 2 (6.3) | 9 (13.4) | 0.15 |
- Estrogen | 2 (5.7) | 3 (9.4) | 5 (7.5) | 0.66 |
- Infection (6 wk) | 2 (5.7) | 0 | 2 (3.0) | 0.49 |
Drop-out, n (%) | 5 (13.5) | 5 (14.3) | 10 (14.9) | 1.00 |
- Consent withdrawn | 1 | 3 | 4 (6) | |
- Newly diagnosed cancer | 2 | 0 | 2 (3.0) | |
- Technical failure | 1 | 0 | 1 (1.5) | |
- Drug interaction | 0 | 1 | 1 (1.5) | |
- Abscess aggravation | 1 | 0 | 1 (1.5) | |
- Follow-up loss | 0 | 1 | 1 (1.5) | |
